Welcome to our dedicated page for VSee Health SEC filings (Ticker: VSEE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VSee Health, Inc. (NASDAQ: VSEE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a telehealth technology and services company in the health information services sector, VSee uses its filings to report on business operations, capital structure, financing arrangements, and Nasdaq listing matters.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for information on VSee’s healthcare technology and telehealth services segments, revenue composition, costs, and risk factors. These core filings outline how the company describes its AI-powered telehealth platform, high-acuity virtual care services, and digital health offerings that integrate secure video, device data, and EHR connectivity for hospital systems, health networks, employers, and enterprise partners.
VSee’s current reports on Form 8-K document material events such as private placements of common stock and warrants, convertible note agreements, warrant exchanges, equity line of credit arrangements, and amendments tied to Nasdaq stockholders’ equity requirements. Recent 8-K and 8-K/A filings describe steps the company has taken to address Nasdaq Listing Rule 5550(b)(1), including capital transactions and conversions of outstanding instruments, as well as governance items like annual meeting scheduling and bylaw amendments affecting quorum.
Through this page, users can also locate proxy materials on Schedule 14A, which detail proposals for director elections, auditor ratification, equity incentive plans, and adjournment authority, along with information on voting rights for common and preferred stock. For those monitoring ownership and compensation, insider transactions and related disclosures can be reviewed via the relevant SEC forms where available.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand complex capital structures, financing terms, and operational disclosures without replacing the full text of the official filings.
VSee Health, Inc. reports that Nasdaq has moved toward delisting its common stock and public warrants after determining the company is not in compliance with multiple listing rules. Nasdaq staff previously denied VSee’s request to continue listing because it failed to timely file its 2024 Form 10-K and 2025 Form 10-Qs, though the 2024 Form 10-K and an amendment were filed in late August 2025.
On September 2, 2025, VSee received an additional notice that it is out of compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least
VSee Health, Inc. (VSEE) amended its 2024 annual report to correct multiple accounting errors, restate interim periods and disclose material financing and acquisition activity. The company identified repeated failures to accrue sales and use taxes, resulting in cumulative accrual increases peaking at $940,130 as of September 30, 2024, and multiple revenue cutoff corrections that moved revenue to deferred revenue and opening retained earnings. The firm recorded substantial purchase accounting adjustments tied to the June 24, 2024 business combination and iDoc acquisition, including adjustments to goodwill and acquired receivables that led to a significant goodwill impairment charge of $56,675,210 and a net loss of $58,134,446 for the year. Financing activity includes an Exchange Note of $2,523,744, a $3,000,000 Quantum Convertible Note, and an Equity Line (ELOC) commitment up to $50,000,000 (floor price later amended). The filing also discloses defaults, numerous convertible and original-issue-discount notes, material fair-value remeasurements, and explicit risks including uncertainty about continuing as a going concern.
VSee Health, Inc. reported a complex 2024 marked by a June 24, 2024 business combination that closed with the acquisition of iDoc and the conversion of legacy securities into the Company’s common stock. Goodwill at closing was $61,591,904 and accumulated goodwill impairment charges reached $56,675,210, contributing to a consolidated net loss of $58,134,446. The Company disclosed a series of accounting restatements and corrections—including recurring failures to accrue sales and use taxes (totaling up to $940,130 as of Sept 30, 2024), revenue cutoff adjustments, and multiple post‑closing accrual errors—that affected retained earnings, deferred revenue and operating expense in 2023 and 2024.
The Company secured multiple financing arrangements: an Equity Purchase Agreement (ELOC) providing up to $50,000,000 in aggregate proceeds (floor price amended to $1.25 on March 20, 2025), an Exchange Note of $2,523,744, and a $3,000,000 Quantum Convertible Note. Several acquired promissory notes and factoring arrangements remain outstanding and some iDoc notes are in default, and management disclosed uncertainty about continuing as a going concern.
VSee Health, Inc. announced that multiple previously issued financial statements for VSee Lab and the combined company should no longer be relied upon and will be restated. The issues affect annual statements for the year ended December 31, 2023 and several quarterly periods in 2023 and 2024, including quarters after the June 24, 2024 business combination.
The company identified errors in areas such as sales and use tax accruals, revenue cut-off, accrued expenses for Digital Health Acquisition Corp. and iDoc Virtual Telehealth Solutions, option valuation, convertible note interest, acquisition accounting, and income tax balances. Management concluded that material weaknesses exist in internal control over financial reporting and that disclosure controls and procedures were not effective; further detail and restated figures will be provided in the 2024 Form 10-K.
VSee Health, Inc. filed a Form 8-K reporting a material event and attached a company press release dated
The filing is concise and primarily serves to disclose the press release and basic terms of the warrants; it does not include financial results, transaction proceeds, or additional operational detail. Readers seeking further material specifics should refer to the attached press release or subsequent filings for revenue, proceeds, or other quantitative impacts.